IL33 and Miyoshi myopathy: In vitro experiments demonstrated that IL‐33 alone did not have obvious cytotoxicity to MM cells, whereas IL‐33 combined with BTZ could synergistically inhibit proliferation and promote apoptosis of MM cells, suggesting that IL‐33 could enhance BTZ‐mediated anti‐MM efficacy.